Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/88758
Title: | Anticoagulant therapy in atrial fibrillation : vitamin K antagonists or novel oral anticoagulant drugs? |
Authors: | Riva, Nicoletta Borg Xuereb, Christian Ageno, Walter |
Keywords: | Anticoagulants (Medicine) Anticoagulants (Medicine) -- Administration Thrombosis |
Issue Date: | 2015 |
Publisher: | Wolters Kluwer Health, Inc. |
Citation: | Riva, N., Xuereb, C. B., & Ageno, W. (2015). Anticoagulant therapy in atrial fibrillation: vitamin K antagonists or novel oral anticoagulant drugs?. Journal of Cardiovascular Medicine, 16(2), 139-141. |
Abstract: | Atrial fibrillation carries a five-fold increased risk of stroke and it is estimated that more than 20% of stroke in elderly patients may be attributable to atrial fibrillation.1 The use of vitamin K antagonists (VKAs) significantly reduces the rate of stroke by 64%,2 but it is hampered by the risk of severe bleeding episodes which occur in 2–13% of the patients.3 As a consequence, only half of the atrial fibrillation patients at high thromboembolic risk receive anticoagulant treatment in clinical practice.4 Recently, novel, direct, target-specific oral anticoagulant drugs have been shown to be at least as effective and at least as safe as VKAs. |
URI: | https://www.um.edu.mt/library/oar/handle/123456789/88758 |
Appears in Collections: | Scholarly Works - FacM&SPat Scholarly Works - FacSoWGer |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
01244665-201502000-00010.pdf Restricted Access | 128.65 kB | Adobe PDF | View/Open Request a copy |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.